Literature DB >> 16736384

Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.

Amy K Dickason-Chesterfield1, Stephanie R Kidd, Steven A Moore, John M Schaus, Bin Liu, George G Nomikos, Christian C Felder.   

Abstract

: 1. The mechanism of anandamide uptake and disposal has been an issue of considerable debate in the cannabinoid field. Several compounds have been reported to inhibit anandamide uptake or fatty acid amide hydrolase (FAAH; the primary catabolic enzyme of anandamide) activity with varying degrees of potency and selectivity. We recently reported the first evidence of a binding site involved in the uptake of endocannabinoids that is independent from FAAH. There are no direct comparisons of purported selective inhibitory compounds in common assay conditions measuring anandamide uptake, FAAH activity and binding activity. 2. A subset of compounds reported in the literature were tested in our laboratory under common assay conditions to measure their ability to (a) inhibit [(14)C]-anandamide uptake in cells containing (RBL-2H3) or cells lacking (HeLa) FAAH, (b) inhibit purified FAAH hydrolytic activity, and (c) inhibit binding to a putative binding site involved in endocannabinoid transport in both RBL and HeLa cell membranes. 3. Under these conditions, nearly all compounds tested inhibited (a) uptake of [(14)C]-anandamide, (b) enzyme activity in purified FAAH preparations, and (c) radioligand binding of [(3)H]-LY2183240 in RBL and HeLa plasma membrane preparations. General rank order potency was preserved within the three assays. However, concentration response curves were right-shifted for functional [(14)C]-anandamide uptake in HeLa (FAAH(-/-)) cells. 4. A more direct comparison of multiple inhibitors could be made in these three assay systems performed in the same laboratory, revealing more information about the selectivity of these compounds and the relationship between the putative endocannabinoid transport protein and FAAH. At least two separate proteins appear to be involved in uptake and degradation of anandamide. The most potent inhibitory compounds were right-shifted when transport was measured in HeLa (FAAH(-/-)) cells suggesting a requirement for a direct interaction with the FAAH protein to maintain high affinity binding of anandamide or inhibitors to the putative anandamide transport protein.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16736384     DOI: 10.1007/s10571-006-9072-6

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  46 in total

Review 1.  Rimonabant Sanofi-Synthélabo.

Authors:  Jose R Fernandez; David B Allison
Journal:  Curr Opin Investig Drugs       Date:  2004-04

Review 2.  Signal transduction activated by cannabinoid receptors.

Authors:  Inés Díaz-Laviada; Lidia Ruiz-Llorente
Journal:  Mini Rev Med Chem       Date:  2005-07       Impact factor: 3.862

Review 3.  Endogenous cannabinoid signaling.

Authors:  D Piomelli; M Beltramo; A Giuffrida; N Stella
Journal:  Neurobiol Dis       Date:  1998-12       Impact factor: 5.996

Review 4.  Evidence for novel cannabinoid receptors.

Authors:  Malcolm Begg; Pál Pacher; Sándor Bátkai; Douglas Osei-Hyiaman; László Offertáler; Fong Ming Mo; Jie Liu; George Kunos
Journal:  Pharmacol Ther       Date:  2005-01-11       Impact factor: 12.310

5.  Chemical and mutagenic investigations of fatty acid amide hydrolase: evidence for a family of serine hydrolases with distinct catalytic properties.

Authors:  M P Patricelli; M A Lovato; B F Cravatt
Journal:  Biochemistry       Date:  1999-08-03       Impact factor: 3.162

Review 6.  Anandamide transport: a critical review.

Authors:  Sherrye T Glaser; Martin Kaczocha; Dale G Deutsch
Journal:  Life Sci       Date:  2005-08-19       Impact factor: 5.037

7.  Accumulation of anandamide: evidence for cellular diversity.

Authors:  Cecilia J Hillard; Abbas Jarrahian
Journal:  Neuropharmacology       Date:  2005-02-19       Impact factor: 5.250

8.  Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity.

Authors:  L De Petrocellis; T Bisogno; J B Davis; R G Pertwee; V Di Marzo
Journal:  FEBS Lett       Date:  2000-10-13       Impact factor: 4.124

Review 9.  Anandamide transport.

Authors:  Matthew J McFarland; Eric L Barker
Journal:  Pharmacol Ther       Date:  2004-11       Impact factor: 12.310

10.  Molecular characterization of a peripheral receptor for cannabinoids.

Authors:  S Munro; K L Thomas; M Abu-Shaar
Journal:  Nature       Date:  1993-09-02       Impact factor: 49.962

View more
  12 in total

1.  Inhibition of the cellular uptake of anandamide by genistein and its analogue daidzein in cells with different levels of fatty acid amide hydrolase-driven uptake.

Authors:  L Thors; J Eriksson; C J Fowler
Journal:  Br J Pharmacol       Date:  2007-08-06       Impact factor: 8.739

Review 2.  Enzymatic pathways that regulate endocannabinoid signaling in the nervous system.

Authors:  Kay Ahn; Michele K McKinney; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2008-04-23       Impact factor: 60.622

Review 3.  The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH).

Authors:  Katerina Otrubova; Cyrine Ezzili; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2011-06-28       Impact factor: 2.823

4.  Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents.

Authors:  Garth Terry; Jeih-San Liow; Eyassu Chernet; Sami S Zoghbi; Lee Phebus; Christian C Felder; Johannes Tauscher; John M Schaus; Victor W Pike; Christer Halldin; Robert B Innis
Journal:  Neuroimage       Date:  2008-03-18       Impact factor: 6.556

5.  Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms.

Authors:  S Maione; E Morera; I Marabese; A Ligresti; L Luongo; G Ortar; V Di Marzo
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

Review 6.  The pharmacology of the cannabinoid system--a question of efficacy and selectivity.

Authors:  Christopher J Fowler
Journal:  Mol Neurobiol       Date:  2007-07-07       Impact factor: 5.590

7.  The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration.

Authors:  John C Ashton; Michelle Glass
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

Review 8.  Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies.

Authors:  David R Janero; Subramanian K Vadivel; Alexandros Makriyannis
Journal:  Int Rev Psychiatry       Date:  2009-04

9.  Identification of intracellular carriers for the endocannabinoid anandamide.

Authors:  Martin Kaczocha; Sherrye T Glaser; Dale G Deutsch
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-23       Impact factor: 11.205

Review 10.  The endocannabinoid system: a new molecular target for the treatment of tobacco addiction.

Authors:  Maria Scherma; Paola Fadda; Bernard Le Foll; Benoit Forget; Walter Fratta; Steven R Goldberg; Gianluigi Tanda
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-11       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.